drugset / Trial / NCT07778810
Epidiolex Trial for Presymptomatic Treatment of Sturge-Weber Syndrome
Phase 2
Recruiting
10 enrolled
Johns Hopkins University
Hugo W. Moser Research Institute at Kennedy Krieger, Inc. · collabJazz Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
Patients with Sturge-Weber syndrome (SWS) are frequently affected by seizures, and seizures are associated with poorer neurological outcomes. To date there is no established means of predicting or preventing seizure onset. Cannabidiol (Epidiolex) was well tolerated in an open label study in this population. This trial will evaluate whether Epidiolex in presymptomatic Sturge-Weber patients may delay the onset of seizures and improve neurological outcome.
Timeline
- Start
- 2026-09-17
- Primary completion
- 2028-07
- Completion
- 2028-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cannabidiol | Other / unclassified | 20 mg/kg | Oral |